Midostaurin with intensive chemotherapy prolonged the overall survival (OS) (4-year survival rate of 51% vs. 44%, hazard ratio (HR) 0.78; 95% confidence interval (CI), 0.63–0.96; one-sided p = 0.009) and event-free survival (EFS) (4-year EFS rate of 28% vs. 21% HR, 0.78; 95% CI, 0.66–0.93; one-sided p = 0.002) compared with a placebo with intensive chemotherapy in a randomized placebo-controlled phase III trial in 717 patients (<60 years old) with newly diagnosed FLT3-mutated AML (FLT3-ITD and FLT3-TKD) (RATIFY) [19]. This evidence concerns the gene FLT3 and acute myeloid leukemia.